Stem Cells http://www.stemcellsportal.com/
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


First published online October 4, 2007
Stem Cells Vol. 26 No. 1 January 2008, pp. 193 -201
doi:10.1634/stemcells.2007-0524; www.StemCells.com
© 2008 AlphaMed Press

OPEN ACCESS ARTICLE
This Article
Free via Open Access: OA
Right arrow OA Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrowOA All Versions of this Article:
2007-0524v1
26/1/193    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Larson, B. L.
Right arrow Articles by Prockop, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Larson, B. L.
Right arrow Articles by Prockop, D. J.

TISSUE-SPECIFIC STEM CELLS

Human Multipotent Stromal Cells Undergo Sharp Transition from Division to Development in Culture

Benjamin L. Larson, Joni Ylöstalo, Darwin J. Prockop

Center for Gene Therapy, Tulane University Health Sciences Center, New Orleans, Louisiana, USA

Key Words. Multipotent stromal cells • Microarray • Mesenchymal stem cells • Transcriptome • Transplantation

Correspondence: Darwin J. Prockop, M.D., Ph.D., Center for Gene Therapy, Tulane University Health Sciences Center, 1430 Tulane Avenue, New Orleans, Louisiana 70112, USA. Telephone: 504-988-7711; Fax: 504-988-7710; e-mail: dprocko{at}tulane.edu

Received July 3, 2007; accepted for publication September 21, 2007.
First published online in STEM CELLS EXPRESS   October 4, 2007.



Human mesenchymal stem cells, or multipotent stromal cells (MSCs), are of interest for clinical therapy, in part because of their capacity for proliferation and differentiation. However, results from clinical trials and in vitro models have been variable, possibly because of MSC heterogeneity and a lack of standardization between MSC in vitro expansion protocols. Here we defined changes in MSCs during expansion in vitro. In low-density cultures, MSCs expand through distinct lag, exponential growth, and stationary phases. We assayed cultures of passage 2 human MSCs from three donors at low density (50 cells per cm2) at approximately 5% confluence on day 2 and after the cultures had expanded to approximately 70% confluence on day 7. On day 2, genes involved in cell division were upregulated. On day 7, genes for cell development were upregulated. The variations among three donors were less than the variation within the expansion of MSCs from a single donor. The microarray data for selected genes were confirmed by real-time polymerase chain reaction, enzyme-linked immunosorbent assay, and FACScan analysis. Approximately 50% of cells at day 2 were in S-phase compared with 10% at day 7. The results demonstrated major differences in early and late stage cultures of MSCs that should be considered in using the cells in experiments and clinical applications.

Disclosure of potential conflicts of interest is found at the end of this article.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS
http://www.epitomics.com
Copyright © 2008 by AlphaMed Press.